Tumor-associated peptide–MHC complexes recognized by LM103 TILs

The target refers to the diverse array of tumor-associated peptide–MHC (Major Histocompatibility Complex) complexes presented on the surface of malignant cells, which are specifically recognized by LM103 tumor-infiltrating lymphocytes (TILs) (ASCO Publications, 2025). LM103 is an autologous adoptive cell therapy consisting of T cells extracted from a patient's tumor, expanded ex vivo, and re-infused to mount an anti-tumor response (PMC11443344). These peptide-MHC complexes serve as the primary ligands for the T-cell receptors (TCRs) present on the LM103 TILs. The peptides are typically derived from neoantigens (mutated proteins) or tumor-associated antigens (overexpressed self-proteins) that are unique to the tumor microenvironment (Frontiers in Immunology, 2024). Upon binding to these complexes, the TILs are activated to exert direct cytotoxic effects, primarily through the release of perforin and granzymes, resulting in tumor cell apoptosis (PMC11556443). This interaction is highly specific and MHC-restricted, requiring the presence of compatible HLA molecules on the tumor surface. LM103 is currently being evaluated in clinical trials for various solid tumors, including metastatic melanoma and non-small cell lung cancer (NCT05902520).

Other names

Tumor-associated antigens (TAAs)NeoantigensPeptide-HLA complexesMHC-restricted tumor antigensTumor-specific antigens (TSAs)

T-cell receptor (TCR)-mediated recognition of peptide-MHC complexes leading to cytotoxic T-lymphocyte activation and tumor cell apoptosis.